Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

References

• QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
   PubMed Web of Science ®Google Scholar
• LeskeMCHeijlAHusseinMFactors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Treatment TrialArch Ophthalmol20031211485612523884
   PubMedGoogle Scholar
• Collaborative Normal-Tension Glaucoma Study GroupComparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressuresAm J Ophthalmol199812644874979780093
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol2002120670171312049574
   PubMed Web of Science ®Google Scholar
• CantorLBClinical pharmacology of bimatoprostExpert Opin Drug Metab Toxicol20051115115716922657
   PubMedGoogle Scholar
• SinghKSpaethGZimmermanTMincklerDTarget pressure – glaucomatologists’ holey grailOphthalmology2000107462963010768323
   PubMed Web of Science ®Google Scholar
• BeanGWCamrasCBCommercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differencesSurv Ophthalmol200853Suppl 1S69S8419038626
   PubMed Web of Science ®Google Scholar
• CantorLBBimatoprost: a member of a new class of agents, the prostamides for glaucoma managementExpert Opin Investig Drugs2001104721731
   PubMed Web of Science ®Google Scholar
• CantorLBAn update on bimatoprost in glaucoma therapyExpert Opin Pharmacother20023121753176212472372
   PubMedGoogle Scholar
• KraussAHWoodwardDFUpdate on the mechanism of action of bimatoprost: a review and discussion of new evidenceSurv Ophthalmol200449Suppl 1S5S1115016556
   PubMed Web of Science ®Google Scholar
• WoodwardDFKraussAHPChenJLaiRKSpadaCSThe pharmacology of bimatoprost (Lumigan™)Surv Ophthamol200145Suppl 4S337S345
   PubMed Web of Science ®Google Scholar
• CamrasCBSharifNWaxMSternschantzJBimatoprost, the prodrug of a prostaglandin analogueBr J Ophthalmol200892686286318523093
   PubMed Web of Science ®Google Scholar
• CamrasCBTorisCBSjoquistBDetection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgeryOphthalmology2004111122193219815582073
   PubMed Web of Science ®Google Scholar
• SharifNAKellyCRCriderJYHuman trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analoguesInvest Ophthalmol Vis Sci200344271572112556403
   PubMed Web of Science ®Google Scholar
• SharifNAKellyCRCriderJYWilliamsGWXuSXOcular hypotensive FP prostaglandin (PG) analogs: PG receptor subtypes binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cellsJ Ocul Pharmacol Ther200319650151514733708
   PubMed Web of Science ®Google Scholar
• HellbergMRSalleeVLMcLaughlinMAPreclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonistJ Ocul Pharmacol Ther200117542143211765147
   PubMed Web of Science ®Google Scholar
• HellbergMRMcLaughlinMASharifNAIdentification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonistSurv Ophthalmol200247Suppl 1S13S3312204698
   PubMed Web of Science ®Google Scholar
• MatiasIChenJDe PetrocellisLProstaglandin ethanolamides (prostamides): in vitro pharmacology and metabolismJ Pharmacol Exp Ther2004309274575714757851
   PubMed Web of Science ®Google Scholar
• SpadaCSKraussAHWoodwardDFBimatoprost and prostaglandin F2α selectively stimulate intracellular calcium signaling in different cat iris sphincter cellsExp Eye Res200580113514515652534
   PubMed Web of Science ®Google Scholar
• WanZWoodwardDFCornellCLBimatoprost, prostamide activity, and conventional drainageInvest Ophthalmol Vis Sci20074894107411517724194
   PubMed Web of Science ®Google Scholar
• TorisCBGabeltBTKaufmanPLUpdate on the mechanism of action of topical prostaglandins for intraocular pressure reductionSurv Ophthalmol200853Suppl 1S107S12019038618
   PubMed Web of Science ®Google Scholar
• StjernschantzJStudies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatmentExp Eye Res200478475976615037110
   PubMed Web of Science ®Google Scholar
• LindenCAlmAEffects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyesActa Ophthalmol Scand19977544124159374251
   PubMedGoogle Scholar
• LindenCAlmALatanoprost twice daily is less effective than once daily: indication of receptor subsensitivity?Curr Eye Res19981765675729663846
   PubMed Web of Science ®Google Scholar
• BrubakerRFSchoffEONauCBEffects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamicsAm J Ophthalmol20011311192411162974
   PubMed Web of Science ®Google Scholar
• ChristiansenGANauCBMcLarenJWJohnsonDHMechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucomaOphthalmology200411191658166215350319
   PubMed Web of Science ®Google Scholar
• DinslageSHueberADiestelhorstMKrieglsteinGThe influence of latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical studyGraefes Arch Clin Exp Ophthalmol2004242865466015241610
   PubMed Web of Science ®Google Scholar
• TorisCBZhanGFanSEffects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressureJ Glaucoma200716218919517473728
   PubMed Web of Science ®Google Scholar
• BahlerCKHowellKGHannCRFautschMPJohnsonDHProstaglandins increase trabecular meshwork outflow facility in cultured human anterior segmentsAm J Ophthalmol2008145111411917988642
   PubMed Web of Science ®Google Scholar
• TorisCBCamrasCBYablonskiMEEffects of exogenous prostaglandins on aqueous humor dynamics and blood aqueous barrier functionSurv Ophthalmol200853Suppl 2S69S7519038626
   PubMed Web of Science ®Google Scholar
• WeinrebRNTorisCBGabeltBTLindseyJDKaufmanPLEffects of prostaglandins on the aqueous humor outflow pathwaysSurv Ophthalmol200247Suppl 1S53S6412204701
   PubMed Web of Science ®Google Scholar
• StjernschantzJAlmALatanoprost as a new horizon in the medical management of glaucomaCurr Opin Ophthalmol199672111710163315
   PubMedGoogle Scholar
• ShawBRLindseyJDWeinrebRNProstaglandin release in a perfused human anterior segment modelJ Glaucoma199321394319920483
   PubMedGoogle Scholar
• LimKSNauCBO’ByrneMMMechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover studyOphthalmology2008115579079518452763
   PubMed Web of Science ®Google Scholar
• OhDJMartinJLWilliamsAJEffect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cellsInvest Ophthalmol Vis Sci20064793887389516936101
   PubMed Web of Science ®Google Scholar
• GatonDDSagaraTLindseyJDIncreased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F (2 alpha)- isopropyl ester treatmentArch Ophthalmol200111981165117011483084
   PubMed Web of Science ®Google Scholar
• NilssonSFDrecollELutjen-DrecollEThe prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkeyInvest Ophthalmol Vis Sci20064794042404916936121
   PubMed Web of Science ®Google Scholar
• RichterMKraussAHWoodwardDFLutjen-DrecollEMorphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamideInvest Ophthalmol Vis Sci200344104419442614507888
   PubMed Web of Science ®Google Scholar
• MishimaHKKiuchiYTakamatsuMRaczPBitoLZCircadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflowSurv Ophthalmol199741Suppl 2S139S1449154290
   PubMed Web of Science ®Google Scholar
• BrubakerRFMechanism of action of bimatoprost (Lumigan™)Surv Ophthalmol200145Suppl 4S347S35111434937
   PubMed Web of Science ®Google Scholar
• KonstasAGKatsimbrisJMLallosNLatanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patientsOphthalmology2005112226226615691561
   PubMed Web of Science ®Google Scholar
• OrzalesiNRossettiLBottoliAFogagnoloPComparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertensionOphthalmology2006113223924616458092
   PubMed Web of Science ®Google Scholar
• OrzalesiNRossettiLBottoliAFumagalliEFogagnoloPThe effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertensionArch Ophthalmol2003121445345712695241
   PubMedGoogle Scholar
• QuarantaLPizzolanteTRivaITwenty-four hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucomaBr J Ophthalmol20089291227123118586898
   PubMed Web of Science ®Google Scholar
• YildrimNSahinAGultekinSThe effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucomaJ Glaucoma2008171363918303382
   PubMed Web of Science ®Google Scholar
• LarssonLIIntraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertensionOphthalmology200110881439144411470697
   PubMed Web of Science ®Google Scholar
• ReissGRLeeDATopperJBrubakerRFAqueous humor flow during sleepInvest Ophthalmol Vis Sci19842567767786724850
   PubMed Web of Science ®Google Scholar
• GeyerOManOWeintraubMSilverDMAcute effect of latanoprost on pulsatile ocular blood flow in normal eyesAm J Ophthalmol2001131219820211228295
   PubMed Web of Science ®Google Scholar
• SponselWEMensahJKielJWEffects of latanoprost and timolol-XE on hydrodynamics in the normal eyeAm J Ophthalmol2000130215115911004288
   PubMed Web of Science ®Google Scholar
• JanulevicienëIHarrisAKagemannLSieskyBMcCranorLA comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patientsActa Ophthalmol Scand200482673073715606472
   PubMedGoogle Scholar
• VetrugnoMCantatoreFGiganteGCardiaLLatanoprost 0.005% in POAG: effects on IOP and ocular blood flowActa Ophthalmol Scand Suppl199822740419972341
   PubMedGoogle Scholar
• LiuCJKoYCChengCYEffect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucomaBr J Ophthalmol200286111236123912386077
   PubMed Web of Science ®Google Scholar
• LiuCJKoYCChengCYChanges in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patientsOphthalmology2002109122241224712466165
   PubMed Web of Science ®Google Scholar
• McKibbinMMenageMJThe effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucomaEye199913Pt 1313410396380
   PubMed Web of Science ®Google Scholar
• RolleTCipulloDVizzeriGMEvaluation and comparison between the effects on intraocular pressure and retinal blood flow of two anti-glaucomatous drugs administered in monotherapy: brimonidine and latanoprost. Preliminary resultsActa Ophthalmol Scand Suppl200078232505211235536
   PubMedGoogle Scholar
• DranceSMCrichtonAMillsRPComparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion in patients with normal-tension glaucomaAm J Ophthalmol199812555855929625541
   PubMed Web of Science ®Google Scholar
• KozOGOzsoyAYarangumeliAKoseSKKuralGComparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trialActa Ophthalmol Scand200785883884317680841
   PubMedGoogle Scholar
• AlagozGGurelKBayerAA comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patientsOphthalmologica20082222889518303228
   PubMed Web of Science ®Google Scholar
• InanUUErmisSSYucelAThe effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: A 3-month clinical trialActa Ophthalmol Scand200381215516012752054
   PubMedGoogle Scholar
• MartínezASánchezMA comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patientsCurr Med Res Opin2006221677316393432
   PubMed Web of Science ®Google Scholar
• NicolelaMTBuckleyARWalmanBEDranceSMA comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vesselsAm J Ophthalmol199612267847898956632
   PubMed Web of Science ®Google Scholar
• SjöquistBStjernschantzJOcular and systemic pharmacokinetics of latanoprost in humansSurv Ophthalmol200247Suppl 1S6S1212204697
   PubMed Web of Science ®Google Scholar
• DuBinerHCookeDDirksMEfficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprostSurv Ophthalmol200145Suppl 4S353S36011434938
   PubMed Web of Science ®Google Scholar
• GandolfiSSimmonsSTSturmRChenKThree-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertensionAdv Ther200118311012111571823
   PubMed Web of Science ®Google Scholar
• KonstasAGMaltezosACGandiSHudginsACStewartWCComparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucomaAm J Ophthalmol19991281152010482089
   PubMed Web of Science ®Google Scholar
• OrzalesiNRossettiLInvernizziTEffect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertensionInvest Ophthalmol Vis Sci20004192566257310937568
   PubMed Web of Science ®Google Scholar
• BronAMDenisPNordmannJPAdditive IOP-reducing effect of latanoprost in patients insufficiently controlled on timololActa Ophthalmol Scand200179328929311401641
   PubMedGoogle Scholar
• NetlandPALandryTSullivanEKTravoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertensionAm J Ophthalmol2001132447248411589866
   PubMed Web of Science ®Google Scholar
• PatelSSSpencerCMLatanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertensionDrugs Aging1996953633788922563
   PubMed Web of Science ®Google Scholar
• CamrasCBSheuWPUnited States Latanoprost-Brimonidine Study groupLatanoprost or brimonidine as treatment of elevated intraocular pressure: a multicenter trial in the United StatesJ Glaucoma200514216116715741820
   PubMed Web of Science ®Google Scholar
• AlmAStjernschantzJEffects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Scandinavian Latanoprost Study GroupOphthalmology199510212174317529098273
   PubMed Web of Science ®Google Scholar
• WatsonPStjernschantzJA six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study GroupOphthalmology199610311261378628543
   PubMed Web of Science ®Google Scholar
• CamrasCBComparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six month masked, multicenter trial in the United States. The United States Latanoprost Study GroupOphthalmology199610311381478628544
   PubMed Web of Science ®Google Scholar
• AungTChewPTYipCCA randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open angle glaucoma and ocular hypertensionAm J Ophthalmol2001131563664211336940
   PubMed Web of Science ®Google Scholar
• O’DonoghueEPA comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: A 3 month randomized study. Ireland Latanoprost Study GroupBr J Ophthalmol200084657958210837379
   PubMed Web of Science ®Google Scholar
• DuBinerHBMrozMShapiroAMDirksMSBrimonidine vs Latanoprost Study GroupA comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multi-center, randomized, double-masked, parallel-group trialClin Ther200123121969198311813932
   PubMed Web of Science ®Google Scholar
• StewartWCDayDGStewartJASchuhrJLathamKEThe efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertensionAm J Ophthalmol2001131563163511336939
   PubMed Web of Science ®Google Scholar
• WaltersTRDuBinerHBCarpenterSPKhanBVanDenburghAMBimatoprost Circadian IOP Study Group: 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trialSurv Ophthalmol200449Suppl 1S26S3515016559
   PubMed Web of Science ®Google Scholar
• SaitoMTakanoRShiratoSEffects of latanoprost and unoprostone when used alone or in combination for open-angle glaucomaAm J Ophthalmol2001132448548911589867
   PubMed Web of Science ®Google Scholar
• SusannaRGiampaniJBorgesASVessaniRMJordaoMLA double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertensionOphthalmology2001108225926311158796
   PubMed Web of Science ®Google Scholar
• MishimaHMasudaKKitazawaYAzumaIAraieMA comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: a 12-week studyArch Ophthalmol199611489299328694726
   PubMedGoogle Scholar
• JampelHDBachararchJSheuWPThe Latanoprost/Unoprostone Study GroupRandomised clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressureAm J Ophthalmol2002134686387112470755
   PubMed Web of Science ®Google Scholar
• KampikAArias-PuenteAO’BrartDPVuoriMLEuropean Latanoprost Study GroupIntraocular pressure-lowering effects of latanoprost and brimonidine therapy inpatients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter studyJ Glaucoma2002112909611912355
   PubMed Web of Science ®Google Scholar
• van der ValkRWebersCASchoutenJSIntraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trialsOphthalmology200511271177118515921747
   PubMed Web of Science ®Google Scholar
• ParrishRKPalmbergPSheuWPThe XLT Study GroupA comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter studyAm J Ophthalmol2003135568870312719078
   PubMed Web of Science ®Google Scholar
• NoeckerRSDirksMSChoplinNTBimatoprost/Latanoprost Study GroupA six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost inpatients with ocular hypertension or glaucomaAm J Ophthalmol20031351556312504698
   PubMed Web of Science ®Google Scholar
• CantorLBHoopJSMorganLWuDunnDCatoiraYThe Bimatoprost-Travoprost Study GroupIntraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertensionBr J Ophthalmol200690111370137316825272
   PubMed Web of Science ®Google Scholar
• AptelFCucheratMDenisPEfficacy and tolerability of prostaglandin analogs. A meta-analysis of randomized controlled clinical trialsJ Glaucoma200817866767319092464
   PubMed Web of Science ®Google Scholar
• ChengJWWeiRLMeta-analysis of 13 randomised controlled trials comparing bimatoprost with latanoprost inpatients with elevated intraocular pressureClin Ther200830462263218498911
   PubMed Web of Science ®Google Scholar
• EyawoONachegaJLefebvrePEfficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysisClin Ophthalmol2009344745619684868
   PubMedGoogle Scholar
• DenisPLafumaAKhoshnoodBMimaudVBerdeauxGA meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapyCurr Med Res Opin200723360160817355741
   PubMed Web of Science ®Google Scholar
• CantorLBWuDunnDCortesAHoopJKnottsSOcular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertensionSurv Ophthalmol200449Suppl 1S12S1815016557
   PubMed Web of Science ®Google Scholar
• CelliniMCaramazzaRBonsantoDProstaglandin analogs and blood-aqueous barrier integrity: a flare cell meter studyOphthalmologica2004218531231715334011
   PubMed Web of Science ®Google Scholar
• JinXQianSSunXEfficacy and safety of bimatoprost 0.03% in patients with elevated intraocularpressure: A comparison with latanorpost 0.005% [in Chinese]Zhong-Guo Shiyong Yan Ke Za Zhi200523712714
   Google Scholar
• ArcieriESSantanaARochaFNGuapoGLCostaVPBlood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trialArch Ophthalmol2005123218619215710814
   PubMedGoogle Scholar
• HepsenIFOzkayaE24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertensionEye200721445345816543930
   PubMed Web of Science ®Google Scholar
• KonstasAGHollóGIrkecMDiurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre studyBr J Ophthalmol200791675776017124241
   PubMed Web of Science ®Google Scholar
• CardasciaNVetrugnoMTrabuccoTEffects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double masked comparison with latanoprost eye drops in patients with open-angle glaucomaCurr Ther Res Clin Exp200364389400
   PubMed Web of Science ®Google Scholar
• ParmaksizSYukselNKarabasVLA comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucomaEur J Ophthalmol2006161738016496249
   PubMed Web of Science ®Google Scholar
• TopouzisFMelamedSDanesh-MeyerHA 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% inpatients with open-angle glaucoma or ocular hypertensionEur J Ophthalmol200717218319017415690
   PubMed Web of Science ®Google Scholar
• NoeckerRJEarlMLMundorfTPeaceJWilliamsRDBimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertensionAdv Ther200320212112812836812
   PubMed Web of Science ®Google Scholar
• NoeckerRJEarlMLMundorfTKSilversteinSMPhillipsMPComparing bimatoprost and travoprost in black AmericansCurr Med Res Opin200622112175218017076978
   PubMed Web of Science ®Google Scholar
• DirksMSNoeckerRJEarlMA 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucomaAdv Ther20062333859416912020
   PubMed Web of Science ®Google Scholar
• DubinerHBSircyMDLandryTComparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressureClin Ther2004261849114996520
   PubMed Web of Science ®Google Scholar
• LiNChenXMZhouYWeiMLYaoXTravoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trialsClin Exp Ophthalmol2006348755764
   PubMed Web of Science ®Google Scholar
• HedmanKAlmAA pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timololEur J Ophthalmol20001029510410887918
   PubMed Web of Science ®Google Scholar
• AlmACamrasCBWatsonPGPhase III Latanoprost studies in Scandinavia, the United Kingdom and the United StatesSurv Ophthalmol199741Suppl 2S105S1109154285
   PubMed Web of Science ®Google Scholar
• HedmanKWatsonPGAlmAThe effect of latanoprost on intraocular pressure during 2 years of treatmentSurv Ophthalmol200247Suppl 1S65S7612204702
   PubMed Web of Science ®Google Scholar
• SuzukiMMishimaHKMasudaKEfficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in JapanJpn J Ophthalmol2000441333810698023
   PubMed Web of Science ®Google Scholar
• AlmAWidengardILatanoprost: experience of 2-year treatment in ScandinaviaActa Ophthalmol Scand2000781717610726794
   PubMedGoogle Scholar
• WatsonPGLatanoprost. Two years’ experience of its use in the United Kingdom. Latanoprost Study GroupOphthalmology1998105182879442782
   PubMed Web of Science ®Google Scholar
• CamrasCBAlmAWatsonPStjernschantzJLatanoprost, a prostaglandin analog, for glaucoma therapy: efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study GroupsOphthalmology199610311191619248942890
   PubMed Web of Science ®Google Scholar
• HedmanKLarssonLThe effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patientsSurv Ophthalmol200247Suppl 10S77S8912204703
   PubMed Web of Science ®Google Scholar
• CostagliolaCDel PreteAVerolinoMMEffect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a three year follow-up. Experience and incidence of side effects in a prospective study on 76 patientsGraefes Arch Clin Exp Ophthalmol2002240537938612073061
   PubMed Web of Science ®Google Scholar
• ZhangWYLi Wan PoADuaHSAzuara-BlancoAMeta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of patients with open-angle glaucoma or ocular hypertensionBr J Ophthalmol200185898399011466259
   PubMed Web of Science ®Google Scholar
• AquinoMVLat-LunaMThe effect of latanoprost vs timolol on intraocular pressure in patients with glaucoma and ocular hypertensionAsian J Ophthalmol19991337
   Google Scholar
• DiestelhorstMAlmegardBComparison of two fixed combinations of latanoprost and timolol in open-angle glaucomaGraefes Arch Clin Exp Ophthalmol199823685775819717652
   PubMed Web of Science ®Google Scholar
• DiestelhorstMRotersSKrieglsteinGKThe effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humor protein concentration in glaucoma patients. A randomized, double – masked comparison with timolol 0.5%Graefes Arch Clin Exp Ophthalmol1997235120269034838
   PubMed Web of Science ®Google Scholar
• MastropasquaLCarpinetoPCiancagliniMGallengaPEA 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucomaOphthalmology1999106355055510080213
   PubMed Web of Science ®Google Scholar
• RuloAHGreveELHoyngPFAdditive effect of latanoprost, a prostaglandin F2α analogue, and timolol in patients with elevated intraocular pressureBr J Ophthalmol199478128999027819171
   PubMed Web of Science ®Google Scholar
• GoldbergICunha-VazJJakobsenJEInternational Travoprost Study GroupComparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertensionJ Glaucoma200110541442211711841
   PubMed Web of Science ®Google Scholar
• FellmanRLSullivanEKRatliffMComparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trialOphthalmology20021095998100811986110
   PubMed Web of Science ®Google Scholar
• HigginbothamEJSchumanJSGoldbergIMThe Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertensionArch Ophthalmol2002120101286129312365906
   PubMed Web of Science ®Google Scholar
• BrandtJDVanDenburghAMChenKWhitcupSMBimatoprost Study Group 1. Comparison of once- or twice-daily bimatoprost with twice daily timolol in patients with elevated IOP: a 3 month clinical trialOphthalmology200110861023103111382623
   PubMed Web of Science ®Google Scholar
• WhitcupSMCantorLBVanDenburghAMChenKA randomized, double-masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertensionBr J Ophthalmol2003871576212488264
   PubMed Web of Science ®Google Scholar
• CohenJSGrossRLCheethamJKTwo-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertensionSurv Ophthalmol200449Suppl 1S45S5215016561
   PubMed Web of Science ®Google Scholar
• WilliamsRDCohenJSGrossRLLong-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4Br J Ophthalmol200892101387139218621791
   PubMed Web of Science ®Google Scholar
• HolmstromSBuchholzPWaltJWickstromJAagrenMAnalytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucomaCurr Med Res Opin200521111875188316307709
   PubMed Web of Science ®Google Scholar
• AlmAVillumsenJTornquistPIntraocular pressure-reducing effect of PhXA41 inpatients with increased eye pressure. A one-month studyOphthalmology19931009131213178371917
   PubMed Web of Science ®Google Scholar
• BucciMGIntraocular pressure-lowering effects of latanoprost mono-therapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study GroupJ Glaucoma199981243010084271
   PubMed Web of Science ®Google Scholar
• ChewPTKHungPTAungTEfficacy of latanoprost inreducing intraocular pressure in patients with primary angle-closure glaucomaSurv Ophthalmol200247Suppl 1S125S12812204708
   PubMed Web of Science ®Google Scholar
• ColemanALLernerFBernsteinPWhitcupSMA 3-month randomized controlled trial of bimatoprost(LUMIGAN)versus combined timolol and dorzolamide(Cosopt)in patients with glaucoma or ocular hypertensionOphthalmology2003110122362236814644719
   PubMed Web of Science ®Google Scholar
• FechtnerRDAiraksinenPJGetsonAJLinesCRAdamsonsIAEfficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. COSOPT versus XALATAN Study GroupsActa Ophthalmol Scand2004821424814982045
   PubMedGoogle Scholar
• TorisCBCamrasCBYablonskiMEEffects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyesOphthalmology19931009129713048371915
   PubMed Web of Science ®Google Scholar
• ThygesenJAaenKTheodorsenFKessingSVPrauseJUShort-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertensionActa Ophthalmol Scand2000781374410726786
   PubMedGoogle Scholar
• GandolfiSACiminoLEffect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprostOphthalmology2003110360961412623831
   PubMed Web of Science ®Google Scholar
• HigginbothamEJFeldmanRStilesMDubinerHFixed Combination Investigative GroupLatanoprost and timolol combination therapy vs monotherapy: one-year randomized trialArch Ophthalmol2002120791592212096962
   PubMed Web of Science ®Google Scholar
• KjellgrenDDouglasGMickelbergFSDranceSMAlmAThe short-time effect of latanoprost on the intraocular pressure in normal pressure glaucomaActa Ophthalmol Scand19957332332367493234
   PubMedGoogle Scholar
• LaibovitxRAVanDenburghAMFelixCComparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma managementArch Ophthalmol20011197994100011448321
   PubMedGoogle Scholar
• ManniGCentofantiMParravanoMOddoneFBucciMGA 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patientsGraefes Arch Clin Exp Ophthalmol2004242976777015241611
   PubMed Web of Science ®Google Scholar
• NordmannJPSoderstromMRoulandJFMalecazeFComparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with β-adrenergic antagonists. French latanoprost study Group and the Swedish Latanoprost Study GroupBr J Ophthalmol200084218118510655195
   PubMed Web of Science ®Google Scholar
• PfeifferNEuropean Latanoprost Fixed Combination Study GroupA comparison of the fixed-combination of latanoprost and timolol with its individual componentsGraefe’s Arch Clin Exp Ophthalmol200224011893899
   PubMed Web of Science ®Google Scholar
• SherwoodMBrandtJBimatoprost Study Groups 1 and 2Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressureSurv Ophthalmol200145Suppl 4S361S36811434939
   PubMed Web of Science ®Google Scholar
• BarnebeyHSOrengo-NaniaSFlowersBEThe safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solutionAm J Ophthalmol200514011715990081
   PubMed Web of Science ®Google Scholar
• EinarsonTRKulinNATingeyDIskedjianMMeta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucomaClinTher2000221215021515
   Google Scholar
• FungATReidSEJonesMPMeta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucomaBr J Ophthalmol2007911626816956912
   PubMed Web of Science ®Google Scholar
• LeBlancRPTwelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2Ophthalmology199810510196019679787370
   PubMed Web of Science ®Google Scholar
• SchumanJSHorwitzBChoplinNTA 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicentre clinical trial. Chronic Brimonidine Study GroupArch Ophthalmol199711578478529230823
   PubMed Web of Science ®Google Scholar
• SerleJBA comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group IIISurv Ophthalmol199641Suppl 1S39S478970248
   PubMed Web of Science ®Google Scholar
• AkmanACetinkayaAAkovaYAComparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combinationEye200519214515115184958
   PubMed Web of Science ®Google Scholar
• SimmonsSTEarlMLThree-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients controlled on β-blockers: tolerance and peak intraocular pressure lowering. Alphagan/Xalatan Study GroupOphthalmology2002109230731411825814
   PubMed Web of Science ®Google Scholar
• SimmonsSTSamuelsonTWComparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN study groupClin Ther200022438839910823361
   PubMed Web of Science ®Google Scholar
• SodhiPKPandeyRMRatanSKEfficacy and safety of brimonidine, dorzolamide and latanoprost as adjunctive therapy in primary open angle glaucomaInt J Clin Pract2003571087587814712889
   PubMed Web of Science ®Google Scholar
• StewartWCStewartJADayDSharpeEDEfficacy and safety of timolol maleate. Latanoprost fixed combination versus timolol maleate and brimonidine given twice dailyActa Ophthalmol Scand200381324224612780402
   PubMedGoogle Scholar
• De FigueiredoCRDe FigueiredoBPOcular blood flow in topical eye hypotensive medication: prospective study (in Portugese)Rev Bras Oftalmol200160471476
   Google Scholar
• Garcia-SanchezJRoulandJFSpiegelDA comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicenter study in EuropeBr J Ophthalmol200488787788315205229
   PubMed Web of Science ®Google Scholar
• WaldockASnapeJGrahamCMEffects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnoses glaucoma patientsBr J Ophthalmol200084771071310873979
   PubMed Web of Science ®Google Scholar
• HodgeWGLachaineJSteffensenIThe efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic reviewBr J Ophthalmol200892171218156371
   PubMed Web of Science ®Google Scholar
• LoneAIRizviASajjadASComparison of latanoprost and dorzolamide in patients with open angle glaucomaJK Science200352628
   Google Scholar
• NiaziMkRajaNComparison of latanoprost and dorzolamide in the treatment of patients with open angle glaucomaJ Ayub Med Coll Abbottabad2004161505315125183
   PubMedGoogle Scholar
• van der ValkRWebersCALumleyTA network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressureJ Clin Epidemiol200962121279128319716679
   PubMed Web of Science ®Google Scholar
• StewartWCKonstasAGNelsonLAKruftBMeta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicinesOphthalmology200811571117112218082886
   PubMed Web of Science ®Google Scholar
• AsraniSZeimerRWilenskyJLarge diurnal fluctuation in intraocular pressure are an independent risk factor in patients with glaucomaJ Glaucoma20009213414210782622
   PubMed Web of Science ®Google Scholar
• StewartWCDayDGJenkinsJNPassmoreCLStewartJAMean intraocular pressure and progression based oncorneal thickness in primary open-angle glaucomaJ Ocul Pharmacol Ther2006221263316503772
   PubMed Web of Science ®Google Scholar
• JonasJBBuddeWStrouxAOberacher-VeltenIMJunemannASingle intraocular pressure measurements and diurnal intraocular pressure profilesAm J Ophthalmol200513961136113715953461
   PubMed Web of Science ®Google Scholar
• BarkanaYAnisSLiebmannJTelloCRitchRClinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucomaArch Ophthalmol2006124679379716769832
   PubMedGoogle Scholar
• CostagliolaCParmeggianiFVirgiliGCircadian changes of intraocular pressure and ocular prefusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucomaGraefes Arch Clin Exp Ophthalmol2008246338939618004586
   PubMed Web of Science ®Google Scholar
• ChengJCaiJWeiRMeta-analysis of medical intervention for normal tension glaucomaOphthalmology200911671243124919450880
   PubMed Web of Science ®Google Scholar
• HarrisAMigliardiRRechtmanEComaprative analysis of the effects of dorzolamide and latanoprost on ocular haemodynamics in normal tension glaucoma patientsEur J Ophthalmol2003131243112635671
   PubMed Web of Science ®Google Scholar
• KiuchiTMotoyamaYOshikaTInfluence of ocular hypotensive eyedrops on intraocular pressure fluctuation with postural change in eyes with normal-tension glaucomaAm J Ophthalmol2007143469369517386282
   PubMed Web of Science ®Google Scholar
• RuloAHGreveELGeijssenHCReduction of introaocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucomaOphthalmology19961038127612828764799
   PubMed Web of Science ®Google Scholar
• TomitaGAraieMKitazawaYA three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patientsEye2004181098494915037889
   PubMed Web of Science ®Google Scholar
• ZeitzOMatthiessenETReussJEffects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamideBMC Ophthalmol20055615811188
   PubMedGoogle Scholar
• BayerAWeilerWOeverhausUSkrotzkiFEStewartWCXplore Observation GroupTwo-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapiesJ Ocul Pharmacol Ther200420647047815684807
   PubMed Web of Science ®Google Scholar
• PetounisAMylopoulosNKandarakisAAndreanosDDimitrakouliasNComparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in GreeceJ Glaucoma200110431632411558817
   PubMed Web of Science ®Google Scholar
• DiestelhorstMGerman Latanoprost Study GroupThe additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. A 6-month randomized, multicenter study. German Latanoprost Study GroupGraefes Arch Clin Exp Ophthalmol2000238543343910901475
   PubMed Web of Science ®Google Scholar
• DiestelhorstMNordmannJTorisCBCombined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapySurv Ophthalmol200247Suppl 1S155S16112204713
   PubMed Web of Science ®Google Scholar
• TorisCBZhanGLZhaoJCamrasCBYablonskiMEPotential mechanism for the additivity of pilocarpine and latanoprostAm J Ophthalmol2001131672272811384567
   PubMed Web of Science ®Google Scholar
• TorisCBAlmACamrasCBLatanoprost and cholinergic agonists in combinationSurv Ophthalmol200247Suppl 1S141S14712204711
   PubMed Web of Science ®Google Scholar
• FriströmBNilssonSEGInteraction of PhXA41, a new prostaglandin analogue, with pilocarpine: a study on patients with elevated intraocular pressureArch Ophthalmol199311156626258489450
   PubMedGoogle Scholar
• KentARVromanDTThomasTJHebertRLCrossonCEInteraction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertensionJ Glaucoma19998425726210464735
   PubMed Web of Science ®Google Scholar
• PatelskaBGreenfieldDSLiebmannJMLatanoprost for uncontrolled glaucoma in a compassionate case protocolAm J Ophthalmol199712432792869439353
   PubMed Web of Science ®Google Scholar
• ShinDHMcCrackenMSBendelREThe additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapyOphthalmology199910623863909951495
   PubMed Web of Science ®Google Scholar
• SusannaRNicolelaMTOgaEAdditive effect of latanoprost to the combination of timolol and dorzolamideJ Glaucoma20009218318610782630
   PubMed Web of Science ®Google Scholar
• O’ConnorDJMartoneJFMeadAAdditive intraocular pressure lowering effect of various medications with latanoprostAm J Ophthalmol2002133683683712036683
   PubMed Web of Science ®Google Scholar
• ChengJWXiGLWeiRLCaiJPLiYEfficacy and tolerability of latanoprost compared to dorzolamide combined with timolol in the treatment of patients with elevated intraocular pressure: a meta-analysis of randomized, controlled trialsJ Ocul Pharmacol Ther2009251556419232016
   PubMed Web of Science ®Google Scholar
• BronAFor the Groupe Europeen d’etudes du Latanoprost. Comparison of latanoprost monotherapy with timolol-dorzolamide combination in patients with open-angle glaucoma or ocular hypertensionJ Fr Ophthalmol2002256604608
   Web of Science ®Google Scholar
• HonrubiaFMLarssonLIThe European Latanoprost Study GroupA comparison of the effect of intraocular pressure of latanoprost 0.005% and fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucomaActa Ophthalmol Scand200280663564112485286
   PubMedGoogle Scholar
• KonstasAGKozobolisVPTersisILeechJStewartWCThe efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucomaEye2003171414612579169
   PubMed Web of Science ®Google Scholar
• KonstasAGPapapanosPTersisIHouliaraDStewartWCTwenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combinationOphthalmology200311071357136012867391
   PubMed Web of Science ®Google Scholar
• SusannaRJrSheuWPLatin American Glaucoma SocietyComparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin AmericaClin Ther200426575576815220019
   PubMed Web of Science ®Google Scholar
• SakaiHShinjyoSNakamuraYComparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzol-amide in chronic primary angle-closure glaucoma (CACG) in Japanese patientsJ Ocul Pharmacol Ther200521648348916386090
   PubMed Web of Science ®Google Scholar
• ChiselitaDAntohiIMedvichiRDanielescuCComparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide: a prospective, randomized, masked, cross-over design studyOftalmologia2005493394516408674
   PubMedGoogle Scholar
• RismanchianAEslamiFMoeiniHAttarzadeHNaderibeniAEfficacy of the latanoprost versus timolol/dorzolamide combination therapy in patients with primary open-angle glaucomaSaudi Med Journal200829338438718327364
   PubMed Web of Science ®Google Scholar
• KonstasAGKozobolisVPTsironiSComparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatmentOphthalmology200811519910318166407
   PubMed Web of Science ®Google Scholar
• FechtnerRDMcCarrollKALinesCRAdamsonsIAEfficacy of the Dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studiesJ Ocular Pharm Ther2005213242249
   Web of Science ®Google Scholar
• KonstasAGBoboridisKTzetziDTwenty-four-hour control with latanoprost-timolol fixed combination therapy vs latanoprost therapyArch Ophthalmol2005123789890216009829
   PubMedGoogle Scholar
• WebersCAvan der ValkRSchoutenJSIntraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol. A meta-analysis of randomized clinical trialsOphthalmology20071141404617070584
   PubMed Web of Science ®Google Scholar
• BrandtJDCantorLBKatzLJBimatoprost/timolol fixed combination: a 3 month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma200817321121618414107
   PubMed Web of Science ®Google Scholar
• European Agency for the Evaluation of Medicinal Products(EMEA) European public assessment report: scientific discussion of Ganfort. http://www.emea.eu.int/humandocs/Humans/EPAR/ganfort/ganfort.htm Accessed April 19, 2010.
   Google Scholar
• HommerAGanfort Investigators Group IA double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertensionEur J Ophthalmology20071715362
   PubMed Web of Science ®Google Scholar
• MartinezASanchezMA comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucomaCurr Med Res Opin20072310231032
   Web of Science ®Google Scholar
• CentofantiMOddoneFVertrugnoMEfficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multi-centre, randomized, investigator-masked, clinical studyEur J Ophthalmol2009191667119123151
   PubMed Web of Science ®Google Scholar
• KonstasAGMikropoulosDHaidichABNtamposKSStewartWCTwenty-four hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucomaBr J Ophthalmol200993448148519019932
   PubMed Web of Science ®Google Scholar
• SchumanJSKatzGJLewisRAEfficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertensionAm J Ophthalmol2005140224225016086946
   PubMed Web of Science ®Google Scholar
• HughesBABacharachJCravenERA three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open-angle glaucoma or ocular hypertensionJ Glaucoma200514539239916148589
   PubMed Web of Science ®Google Scholar
• HenryJCKesslerTLMallickSTravoprost/timolol Study GroupComparison of the safety and IOP-lowering efficacy of travoprost 0.004%/timolol 0.5% fixed combination to the concomitant administration of Xalatan and timolol 0.5% [Abstr 446] ARVO, Fort Lauderdale, 2006
   Google Scholar
• RheeDJPeaceJHMallickSLandryTABergaminiMVA study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertensionClin Ophthalmol20082231331919668722
   PubMedGoogle Scholar
• TeusMAMigliorSLaganovskaGEfficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertensionClin Ophthalmol2009362963619997566
   PubMedGoogle Scholar
• DenisPLafumaAJeanbatVLaurendeauCIntraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations: a retrospective, multicentre, cross-sectional studyClin Drug Investig20082812767776
   Web of Science ®Google Scholar
• ZimmermanTJHahnSRGelbLTanHKimEEThe impact of ocular adverse effects in patients treated with topicl prostaglandin analogs: changes in prescription patterns and patient persistenceJ Oc Pharm Ther2009252145151
   PubMed Web of Science ®Google Scholar
• HonrubiaFGarcia-SanchezJPoloVMatinez de la CasaJMSotoJConjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomized control trialsBr J Ophthalmol200993331632119019922
   PubMed Web of Science ®Google Scholar
• StjernschantzJWFrom PGF2α-isopropyl ester to latanoprost: a review of the development of Xalatan. The Proctor lectureInvest Ophthalmol Vis Sci20014261134114511328719
   PubMed Web of Science ®Google Scholar
• WistrandPJStjernschantzJOlssonKThe incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye colorSurv Ophthalmol199741Suppl 2S129S1389154289
   PubMed Web of Science ®Google Scholar
• AlmASchoenfelderJMcDermottJA 5-year, multicentre, open-label, safety study of adjunctive latanoprost therapy for glaucomaArch Ophthalmol2004122795796515249358
   PubMedGoogle Scholar
• GriersonIJonssonMCracknellKLatanoprost and pigmentationJpn J Ophthalmol200448660261215592791
   PubMed Web of Science ®Google Scholar
• ChouSYChouCKKuangTMIncidence and severity of iris pigmentation on latanoprost-treated glaucoma eyesEye200519778478715359238
   PubMed Web of Science ®Google Scholar
• Latanoprost-Induced iris Pigmentation Study GroupIncidence of a latanoprost-induced increase in iris pigmentation in Japanese eyesJpn J Ophthalmol2006502969916604382
   PubMed Web of Science ®Google Scholar
• LindquistNGLarssonBSStjernschantzJIncreased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogueExp Eye Res19996943143610504276
   PubMed Web of Science ®Google Scholar
• PfeifferNGriersonIGoldsmithHHistological effects in the iris after 3 months of latanoprost therapy: The Mainz 1 StudyArch Ophthalmol2001119219119611176979
   PubMedGoogle Scholar
• ProtaGVincensiMRNapolitanoASelenGStjernschantzJLatanoprost stimulates eumelanogenesis in iridial melanocyte of cynomolgus monkeysPigment Cell Res20001314715010885672
   PubMedGoogle Scholar
• StjernschantzJWAlbertDMHuDNDragoFWistrandPJMechanism and clinical significance of prostaglandin-induced iris pigmentationSurv Ophthalmol200247Suppl 1S162S17512204714
   PubMed Web of Science ®Google Scholar
• BitoLZProstaglandins: a new approach to glaucoma management with a new, intriguing side effectSurv Ophthalmol199741Suppl 2S1S149154271
   PubMed Web of Science ®Google Scholar
• GriersonICracknellKPPfeifferNThe iris after prostanoid treatmentCurr Opin Ophthalmol200112211211811224717
   PubMed Web of Science ®Google Scholar
• AlbertDMGreenWRZimbricMLIris melanocyte histopathologic features of latanoprost- and non-latanoprost treated patientsArch Ophthalmol2004122111680168515534130
   PubMedGoogle Scholar
• HuDNStjernschantzJMcCormickSAEffect of prostaglandins A2, E1, F2α and latanoprost on cultured human iridal melanocytesExp Eye Res200070111312010644427
   PubMed Web of Science ®Google Scholar
• LoefflerKUSahmMSpitznasMShort-time application of latanoprost does not stimulate melanogenesis in bovine ocular melanin-containing cells in vitroOphthalmic Res200133210210611244356
   PubMed Web of Science ®Google Scholar
• AlmAGriersonIShieldsMBSide effects associated with prostaglandin analog therapySurv Ophthalmol200853Suppl 2S93S10519038628
   PubMed Web of Science ®Google Scholar
• JohnstoneMAHypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprostAm J Ophthalmol2001132447248411589866
   PubMed Web of Science ®Google Scholar
• WandMLatanoprost and hyperpigmentation of eyelashesArch Ophthalmol19971159120612089298071
   PubMed Web of Science ®Google Scholar
• ChibaTKashiwagiKChibaNA prospective study of iridal pigmentation and eyelash changes due to ophthalmic treatment with latanoprostJpn J Ophthalmol200448214114715060793
   PubMed Web of Science ®Google Scholar
• ShaikhMYBodlaAAHypertrichosis of the eyelashes from prostaglandin analog use: a blessing or a bother to the patient?J Ocul Pharmacol Ther2006221767716503779
   PubMed Web of Science ®Google Scholar
• JohnstoneMAAlbertDMProstaglandin-induced hair growthSurv Ophthalmol200247Suppl 10S185S20212204716
   PubMed Web of Science ®Google Scholar
• ChenCSWellsJCraigJETopical prostaglandin F(2 alpha)analog induced poliosisAm J Ophthlamol20041375965966
   Web of Science ®Google Scholar
• WaheedKLaganowskiHBilateral poliosis and granulomatous anterior uveitis associated with latanoprost use and apparent hypotrichosis onits withdrawalEye200115Pt 334734911450742
   PubMed Web of Science ®Google Scholar
• HerndonLWRobertD WilliamsWandMAsraniSIncreased periocular pigmentation with ocular hypotensive lipid use in African AmericansAm J Ophthalmol2003135571371512719085
   PubMed Web of Science ®Google Scholar
• KookMSLeeKIncreased eyelid pigmentation associated with latanoprost useAm J Ophthalmol2000129680480610926995
   PubMed Web of Science ®Google Scholar
• WandMRitchRIsbeyEKLatanoprost and periocular skin changesArch Ophthalmol2001119461461511296032
   PubMedGoogle Scholar
• DoshiMEdwardDPOsmanovicSClinical course of bimatoprost-induced periocular skin changes in CaucasiansOphthalmology2006113111961196716935336
   PubMed Web of Science ®Google Scholar
• GallowayGDEkeTBroadwayDCPeriocular cutaneous pigmentary changes associated with bimatoprost useArch Ophthalmol2005123111609161016286629
   PubMedGoogle Scholar
• ChenJDinhTWoodwardDFBimatoprost: mechanism of ocular surface hyperaemia associated with topical therapyCardiovasc Drug Res2005233231246
   Google Scholar
• EasthopeSEPerryCMTopical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertensionDrugs Aging200219323124812027782
   PubMed Web of Science ®Google Scholar
• KapurROsmanovicSToyranSEdwardDPBimatoprost induced periocular skin hyperpigmentation: Histopathological studyArch Ophthalmol2005123111541154616286616
   PubMedGoogle Scholar
• Abdel-MalekZASwopeVBAmornsiripanitchNIn vitro modulation of proliferation and melanisation of S91 melanoma cells by prostaglandinsCancer Res1987314146
   Google Scholar
• SodhiPKVermaLRatanSKIncreased periocular pigmentation with ocular hypotensive lipid use in African AmericansAm J Ophthalmol20041374783
   Web of Science ®Google Scholar
• MiyakeKSugiyamaSNorimatsuIOzawaTPrevention of cystoid macular oedema after lens extraction by topical indomethacin (III) radioimmunoassay measurement of prostaglandins in the aqueous during and after lens extraction proceduresAlbrecht Von Graefes Arch Klin Exp Ophthalmol19782098388311170
   PubMedGoogle Scholar
• WeiszJMBresslerNMBresslerSBKetorolac treatment of pseudophakic cystoid macular oedema identified more than 24 months after cataract extractionOphthalmology199910691656165910485530
   PubMed Web of Science ®Google Scholar
• MiyakeKIbarakiNProstaglandins and cystoid macular edemaSurv Ophthalmol200247Suppl 1S203S21812204717
   PubMed Web of Science ®Google Scholar
• MiyakeKOtaIMaekuboKIchihashiSMiyakeSLatanoprost accelerates disruption of the blood aqueous barrier and the incidence of angiographic cystoid macular oedema in early post-operative pseudophakiasArch Ophthalmol1999117134409930158
   PubMed Web of Science ®Google Scholar
• SchumerRACamrasCBMandahlAKLatanoprost and cystoid macular oedema: is there a causal relation?Curr Opin Ophthalmol20001129410010848227
   PubMedGoogle Scholar
• MiyakeKShirasawaEHikitaMSynthesis of prostaglandin E inrabbit eyes with topically applied epinephrineInvest Ophthalmol Vis Sci19882923323343338893
   PubMed Web of Science ®Google Scholar
• AyyalaRSCruzDAMargoCECystoid macular oedema associated with latanoprost in aphakic and pseudophakic eyesAm J Ophthalmol199812646026049780112
   PubMed Web of Science ®Google Scholar
• MoroiSEGottfredsdottirMSSchteingartMTCystoid macular oedema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertensionOphthalmology199910651024102910328408
   PubMed Web of Science ®Google Scholar
• RoweJAHattenhauerMGHermanDCAdverse side effects associated with latanoprostAm J Ophthalmol199712456836859372723
   PubMed Web of Science ®Google Scholar
• WandMGaudioARCystoid macular oedema associated with ocular hypotensive lipidsAm J Ophthalmol2002133340340511860980
   PubMed Web of Science ®Google Scholar
• WarwarREBullockJDBallalDCystoid macular oedema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patientsOphthalmology199810522632689479285
   PubMed Web of Science ®Google Scholar
• LimaMCParanhosASalimSVisually significant cystoid macular oedema in pseudophakic and aphakic patients with glaucoma receiving latanoprostJ Glaucoma20009431732110958605
   PubMed Web of Science ®Google Scholar
• WandMGaudioARShieldsMBLatanoprost and cystoid macular oedema in high risk aphakic or pseudophakic eyesJ Cataract Refract Surg20012791397140111566522
   PubMed Web of Science ®Google Scholar
• ChangJHMcCluskeyPMissottenTUse of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema?Br J Ophthalmol200892791692118460537
   PubMed Web of Science ®Google Scholar
• FuruichiMChibaTAbeKCystoid macular oedema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocualr barierJ Glaucoma200110323323611442189
   PubMed Web of Science ®Google Scholar
• FechtnerRDKhouriASZimmermanTJAnterior uveitis associated with latanoportsAm J Ophthalmol1998126137419683147
   PubMed Web of Science ®Google Scholar
• LindenCAlmAThe effect on intraocular pressure of latanoprost once or four times dailyBr J Ophthalmol200185101163116611567957
   PubMed Web of Science ®Google Scholar
• MarkomichelakisNNKostakouAHalkiadakisIEfficacy and safety of latanoprost in eyes with uveitic glaucomaGraefes Arch Clin Exp Ophthalmol2009247677578019184081
   PubMed Web of Science ®Google Scholar
• WandMGilbertCMLiesegangTJLatanoprost and herpes simplex keratitisAm J Ophthalmol1999127560260410334356
   PubMed Web of Science ®Google Scholar
• KrollDMSchumanJSReactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucomaAm J Ophthalmol2002133340140311860979
   PubMed Web of Science ®Google Scholar
• KaufmanHEVarnellEDThompsonHWLatanoprost increases the severity and recurrence of herpetic keratitis in the rabbitAm J Ophthalmol1999127553153610334345
   PubMed Web of Science ®Google Scholar
• BeanGReardonGZimmermanTJAssociation between ocular herpes simplex virus and topical ocular hypotensive therapyJ Glaucoma200413536136415354072
   PubMed Web of Science ®Google Scholar
• BrowningDJPerkinsSLLarkKKIris cyst secondary to latanoprost mimicking iris melanomaAm J Ophthalmol2003135341942112614778
   PubMed Web of Science ®Google Scholar
• KrohnJHoveVKIris cysts associated with topical administration of latanoprostAm J Ophthalmol1999127191939933009
   PubMed Web of Science ®Google Scholar
• LaiICKuoMTTengLMIris pigment epithelial cyst induced by topical administration of latanoprostBr J Ophthalmol200387336612598462
   PubMed Web of Science ®Google Scholar
• PruthiSKashaniSRubenSBilateral iris cyst secondary to topical latanoprostActa Ophthalmol200886223323417888084
   PubMed Web of Science ®Google Scholar
• SodhiPKIris cyst secondary to latanoprost mimicking iris melanomaAm J Ophthalmol2003136480, author reply 780781
   Web of Science ®Google Scholar
• HednerJEvertsBMoollerCSLatanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluationArch Ophthalmol1999117101305130910532438
   PubMedGoogle Scholar
• SusannaRMedeirosFAThe pros and cons of different prostanoids in the medical management of glaucomaCurr Opin Ophthalmol200112214915611224723
   PubMed Web of Science ®Google Scholar
• Swedish Adverse Drug Reactions Advisory CommitteeRespiratory tract reactions to latanoprostBull SARAC19986745
   Google Scholar
• Pfizer. Xalatan (Latanoprost 0.005%) ophthalmic solution: prescribing information. Available online. 2009
   Google Scholar
• MitraMChangBJamesTDrug points. Exacerbation of angina associated with latanoprostBMJ200132378311588081
   PubMed Web of Science ®Google Scholar
• PeakASSuttonBMSystemic adverse effects associated with topically applied latanoprostAnn Pharmacother19983245045059562149
   PubMed Web of Science ®Google Scholar
• WestonBCMigraine headache associated with latanoprostArch Ophthalmol2001119230030111176999
   PubMedGoogle Scholar
• AlmAWidengardIKjellgrenDLatanoprost administration once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timololBr J Ophthalmol199579112167880782
   PubMed Web of Science ®Google Scholar
• HyltonCRobinALUpdate on prostaglandin analogsCurr Opin Ophthalmol2003142656912698043
   PubMedGoogle Scholar
• HerndonLWAsraniSGWilliamsGHParadoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprostArch Ophthalmol2002120684784912049597
   PubMedGoogle Scholar
• PerryCMMcGavinJKCulyCRIbbotsonYLatanoprost. An update of its use in glaucoma and ocular hypertensionDrugs Aging200320859763012795627
   PubMed Web of Science ®Google Scholar
• GoldbergILiXYSelaruPPaggiarinoDA 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertensionEur J Ophthalmol200818340841618465724
   PubMed Web of Science ®Google Scholar
• WeinrebRNCompliance with medical treatment in glaucomaJ Glaucoma19921134136
   Google Scholar
• ReardonGSchwartzGFMozaffariEPatient persistency with topical ocular hypotensive therapy in a managed care populationAm J Ophthalmol2004137Suppl 1S3S1214697909
   PubMed Web of Science ®Google Scholar
• GurwitzJHGlynnRJMananeMTreatment for glaucoma: adherence by the elderlyAm J Public Health19938357117168484454
   PubMed Web of Science ®Google Scholar
• StewartWCKruftBNelsonLAStewartJAOphthalmologist attitudes regarding fixed combination treatment for glaucoma in the European UnionEur J Ophthalmol200919458859319551673
   PubMed Web of Science ®Google Scholar
• BaudouinCSide effects of antiglaucomatous drugs on the ocular surfaceCurr Opin Ophthalmol199672808610163327
   PubMedGoogle Scholar
• HamacherTAirksinenJSaarelaVEfficacy and safety levels of preserved and preservative free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysisActa Ophthalmol Suppl (Oxf)2008242141918752510
   PubMedGoogle Scholar
• UusitaloHKaarnirantaKRopoAPharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteersActa Ophthalmol Suppl (Oxf)200824271318752509
   PubMedGoogle Scholar
• GrossRLPeaceJHSmithSEDuration of IOP reduction with travoprost BAK-free solutionJ Glaucoma200817321722218414108
   PubMed Web of Science ®Google Scholar
• LewisRAKatzGWeissMJTravoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacyJ Glaucoma20071619810317224758
   PubMed Web of Science ®Google Scholar
• SchmierHalpernMTJonesMLThe economic implications of glaucoma. A literature reviewPharmacoeconomics200725428730817402803
   PubMed Web of Science ®Google Scholar
• BalkrishnanRBondJBByerlyWGCamachoFTAndersonRTMedication-related predictors of health-related quality of life in glaucoma patients enrolled in a medicare health maintenance organizationAm J Geriatr Pharmacother200312758115555469
   PubMedGoogle Scholar
• HaverkampFWuenschSFuchsMIntraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatmentsEur J Ophthalmol200414540741515506603
   PubMed Web of Science ®Google Scholar
• DunkerSSchmukerAMaierHLatanoprost/Timolol Fixed Combination Study GroupTolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timololAdv Ther200724237638617565929
   PubMed Web of Science ®Google Scholar
• PillunatLLarssonLIthe European and Canadian Latanoprost Study GroupIntraocualr pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open-angle glaucomaBr J Ophthalmol200387121492149614660460
   PubMed Web of Science ®Google Scholar
• ZimmermanTJStewartWCLatanoprost Axis Study GroupIntraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatmentsJ Ocul Pharmacol Ther200319540541514583133
   PubMed Web of Science ®Google Scholar
• TsaiJCA comprehensive perspective on patient adherence to topical glaucoma therapyOphthalmology2009116Suppl 11S30S3619837258
   PubMed Web of Science ®Google Scholar
• HeijlALeskeMCBengtssonBReduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trialArch Ophthalmol2002120101268127912365904
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group/the effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucomaAm J Ophthalmol199812644985059780094
   PubMed Web of Science ®Google Scholar
• AGIS InvestigatorsThe Advanced Glaucoma Intervention Study(AGIS): 7. The relationship between control of intraocular pressure and visual field deteriorationAm J Ophthalmol20011304429440
   Web of Science ®Google Scholar
• American Academy of OphthalmologyPreferred practice pattern: primary open-angle glaucomaSan Francisco (CA)American Academy of Ophthalmology2005
   Google Scholar
• European Glaucoma SocietyTerminology and guidelines for glaucoma3rd edSavona, ItalyDogma2008
   Google Scholar
• CarrollSCGaskinBJGoldbergIDanesh-MeyerHVGlaucoma prescribing trends in Australia and New ZealandClin Experiment Ophthalmol200634321321816671900
   PubMed Web of Science ®Google Scholar
• CurranMPOrmanJSBimatoprost/timolol: A review of its use in glaucoma and ocular hypertensionDrugs Aging200926216918419220073
   PubMed Web of Science ®Google Scholar